Vision Loss in America 2026
Vision loss affects a remarkably large and rapidly growing share of the American population, ranging from minor difficulty reading fine print to complete and irreversible blindness. As the population ages and chronic conditions such as diabetes become more prevalent, the burden of eye disease in the United States continues to climb. According to the most recent 2024 National Health Interview Survey (NHIS), an estimated 49.5 million American adults aged 18 and older report experiencing some degree of difficulty seeing, including 3.8 million adults who have significant trouble seeing even while wearing glasses, and 420,000 Americans who report being completely unable to see. These figures, drawn directly from a nationally representative federal survey, illustrate just how widespread visual impairment has become across every region and demographic group in the country.
What makes the 2026 vision loss landscape especially significant is the scale of the financial and societal burden tied to this growing health challenge. Research funded and published by the Centers for Disease Control and Prevention (CDC) found that vision loss and blindness cost the US economy $134.2 billion annually, a figure that captures both direct medical expenses and the indirect costs of lost productivity and informal caregiving. With the youngest Baby Boomers reaching retirement age and the National Eye Institute (NEI) projecting that the number of Americans with significant visual impairment or blindness will double to more than 8 million by 2050, addressing the causes, costs, and care gaps surrounding vision loss has become an urgent national public health priority. This article draws exclusively on verified data from US government sources — including the CDC, the National Eye Institute (NIH/NEI), and the National Center for Health Statistics — to present an accurate, comprehensive statistical picture of blindness and vision loss in the United States in 2026.
Blind and Vision Loss Key Facts in the US 2026
Before exploring detailed statistical breakdowns, the following key facts establish the scope, causes, and economic weight that define vision loss and blindness across America today.
VISION LOSS & BLINDNESS KEY FACTS SNAPSHOT — US 2026
======================================================
Adults Reporting Vision Difficulty ████████████████████ 49.5 million
Adults Unable to See at All ███░░░░░░░░░░░░░░░░░ 420,000
Living w/ Uncorrectable Vision Loss ████████████████░░░░ 7+ million
Americans Who Are Blind ████████████████░░░░ 1+ million
Total Annual Economic Burden ████████████████████ $134.2 billion
Avg Annual Cost Per Affected Person ████████████████░░░░ $16,838
Projected Cases by 2050 ████████████████████ 8+ million (doubling)
People 80+ Share of All Blindness ████████████████████ 69%
| Key Fact | Detail |
|---|---|
| Adults reporting any vision difficulty (2024) | 49.5 million US adults |
| Adults with significant trouble seeing (with glasses) | 3.8 million |
| Adults who cannot see at all | 420,000 |
| Americans with uncorrectable vision loss | More than 7 million |
| Americans who are legally or fully blind | More than 1 million |
| Increase vs. 2012 prior national estimate | 68% higher than earlier study |
| Total annual US economic burden (2017 data) | $134.2 billion |
| Average annual cost per person affected | $16,838 |
| Projected total cases by 2050 | More than 8 million (doubling) |
| Share of all blindness occurring in people 80+ | 69% |
| Population 80+ share of overall US population | 8% |
| People with risk-factor eye disease (age 40+) | More than 28 million |
Source: American Foundation for the Blind, analysis of 2024 National Health Interview Survey (NHIS)/IPUMS data, 2025; Prevent Blindness/CDC Vision Health Initiative, “Prevalence of Visual Acuity Loss or Blindness in the US,” JAMA Ophthalmology, 2021; CDC, Economic Studies, Vision and Eye Health, updated 2024; National Eye Institute (NIH), 2016
The 49.5 million American adults reporting some degree of vision difficulty represents one of the largest disability-related populations tracked by any federal health survey, underscoring that visual impairment is far from a rare or niche concern. Importantly, the 2021 JAMA Ophthalmology study, conducted by researchers from the University of Washington’s Institute for Health Metrics and Evaluation in partnership with the CDC’s Vision Health Initiative, found that earlier prevalence estimates had significantly understated the true scope of the problem — the corrected estimate came in 68% higher than the widely cited 2012 study, largely because the new methodology incorporated younger adults and people living in group settings such as nursing homes, populations that earlier surveys had often excluded.
The economic dimension of vision loss is equally striking. The CDC’s landmark 2022 cost-of-illness study, published in the journal Ophthalmology, found that the total annual US economic burden reaches $134.2 billion, translating to an average cost of $16,838 per affected person each year. This burden disproportionately concentrates among older Americans: people aged 80 and older make up only 8% of the total US population but account for 69% of all blindness cases, a pattern driven by the cumulative, age-related progression of leading eye diseases. As the US population continues to age over the coming decades, the National Eye Institute’s projection that cases will double to more than 8 million by 2050 signals that vision health will demand significantly greater public health attention and resources in the years ahead.
Leading Causes of Blindness and Vision Loss in the US 2024
Identifying the specific eye diseases responsible for vision loss is essential for guiding screening priorities, treatment funding, and public health messaging. CDC and NIH-funded research consistently points to four age-related conditions as the dominant drivers.
LEADING CAUSES OF VISION LOSS — US ADULTS 40+ (2024)
========================================================
(Estimated number of affected Americans, in millions)
Cataracts ████████████████████ 20.5 million
Diabetic Retinopathy ████████░░░░░░░░░░░░ 4.1 million
Glaucoma ████░░░░░░░░░░░░░░░░ 2.2 million
Age-Related Macular ███░░░░░░░░░░░░░░░░░ 1.8 million
Degeneration (AMD)
Vision-Threatening DR █░░░░░░░░░░░░░░░░░░░ 899,000
| Eye Disease | Americans Affected (40+) | Clinical Notes |
|---|---|---|
| Cataracts | 20.5 million adults | Leading cause of poor vision in the US |
| Diabetic retinopathy (DR) | 4.1 million adults | Leading cause of blindness in working-age adults |
| Vision-threatening diabetic retinopathy | 899,000 adults | Most severe DR subgroup |
| Glaucoma | 2.2 million adults | Second-leading cause of blindness overall |
| Age-related macular degeneration (AMD) | 1.8 million adults | Leading cause of severe vision loss in older adults |
| At elevated risk for AMD vision loss | 7.3 million additional adults | Early-stage/high-risk AMD |
| Patients with DR not receiving timely eye exams | Up to 50% | Diagnosed too late for effective treatment |
| Refractive error correction potential | Could improve vision for 150 million Americans | All ages, all severities |
Source: National Eye Institute (NIH), Eye Diseases Prevalence Research Group, Archives of Ophthalmology, 2004 (with NEI 2020 updated projections); CDC, About Common Eye Disorders and Diseases, updated 2025
Cataracts remain by far the most common cause of impaired vision in the United States, affecting an estimated 20.5 million American adults age 40 and older — more than four times the number affected by glaucoma. While cataracts are highly treatable through surgery, the sheer scale of the affected population means that cataract-related vision loss continues to place enormous demand on ophthalmologic surgical capacity nationwide, particularly as the eligible population is projected to climb to 30.1 million in the coming decades according to NEI-funded projections.
Diabetic retinopathy stands out as a particularly urgent public health concern because it strikes during working-age adulthood rather than predominantly in old age, making it the leading cause of blindness among working-age Americans. The CDC’s data reveals a critical care gap: as many as 50% of patients with diabetic retinopathy are not getting timely eye examinations or are diagnosed too late for treatment to meaningfully preserve vision, despite well-established evidence that managing blood sugar, blood pressure, and cholesterol can substantially reduce this risk. Meanwhile, glaucoma’s reputation as the second-leading cause of blindness in the US is compounded by its insidious nature — the disease frequently progresses with no early symptoms, meaning that routine comprehensive eye exams remain the only reliable way to catch it before irreversible optic nerve damage occurs.
Vision Loss Prevalence by Age and Race in the US 2024
Age and race are two of the most powerful predictors of who experiences vision loss and blindness in America, with risk climbing dramatically after age 60 and varying meaningfully across racial and ethnic groups.
VISION LOSS RISK FACTORS BY AGE/RACE — US 2024
==================================================
VISION LOSS PREVALENCE GROWTH BY AGE:
Age 40+ (1 in 28 at risk, 2004 baseline) ████░░░░░░░░░░░░░░░░ 3.3 million
Age 60+ (sharp increase begins) ████████████░░░░░░░░ Marked rise
Age 80+ (69% of all blindness cases) ████████████████████ Highest burden
RACIAL DISTRIBUTION OF US ADULTS WITH VISION LOSS (2024 NHIS):
White █████████████████████ 71.2% (35.3 million)
Black/African Am. ███████░░░░░░░░░░░░░░ 13.5% (6.7 million)
Asian ██░░░░░░░░░░░░░░░░░░░ 4.2% (2.1 million)
American Indian/AK █░░░░░░░░░░░░░░░░░░░░ 2.6% (1.3 million)
| Demographic Factor | Statistic | Source |
|---|---|---|
| Blindness/low vision prevalence, age 40+ (baseline) | 3.3 million (1 in 28) | NEI/NIH, 2004 study |
| Projected blindness/low vision by 2020 | 5.5 million | Same study |
| Population 80+ share of total US population | 8% | NEI/NIH |
| Population 80+ share of all blindness | 69% | NEI/NIH |
| White Americans with vision loss (2024 NHIS) | 35.3 million (71.2%) | American Foundation for the Blind/NHIS, 2025 |
| Black/African American adults with vision loss | 6.7 million (13.5%) | Same source |
| Asian American adults with vision loss | 2.1 million (4.2%) | Same source |
| American Indian/Alaska Native adults with vision loss | 1.3 million (2.6%) | Same source |
| Multiple/other race adults with vision loss | 1.1 million (2.2%) | Same source |
| Geographic concentration of highest per-capita blindness | Washington DC, Mississippi, Louisiana, Florida | NIH/NCBI Bookshelf, population health data |
Source: National Eye Institute (NIH), Eye Diseases Prevalence Research Group/Congdon N et al., Archives of Ophthalmology, 2004; American Foundation for the Blind, analysis of 2024 National Health Interview Survey (NHIS), 2025; NCBI Bookshelf, “Making Eye Health a Population Health Imperative,” National Academies Press
The relationship between advancing age and vision loss is one of the most consistent findings across decades of NIH-funded epidemiological research. While people aged 80 and older represent just 8% of the total US population, this same group accounts for a staggering 69% of all blindness cases nationwide — a concentration ratio that highlights how dramatically eye disease risk compounds in the oldest segments of the population. This pattern is being closely watched by federal health planners because the rapid aging of the Baby Boomer generation means the absolute number of older Americans, and therefore the absolute burden of age-related vision loss, will continue rising sharply through the 2030s and 2040s.
Racial composition data from the 2024 NHIS shows that non-Hispanic white Americans comprise 71.2% (35.3 million) of all adults reporting vision loss, reflecting both this group’s larger overall share of the US population and documented differences in underlying disease prevalence. However, the CDC’s health equity research emphasizes that raw population counts can obscure important per-capita disparities: when adjusted for population size, certain communities — including some Black, Hispanic, and Native American populations — face disproportionately higher rates of specific causes of vision loss, such as diabetic retinopathy linked to elevated diabetes prevalence and glaucoma linked to documented genetic risk factors. Geographic data further reinforces these patterns, with southern states including Mississippi, Louisiana, and Florida recording among the highest per-capita blindness rates in the country, a disparity researchers link to differences in healthcare access, poverty rates, and the regional prevalence of diabetes and hypertension.
Vision Loss Economic Burden in the US 2024
The financial cost of vision loss and blindness extends far beyond direct medical bills, encompassing nursing home care, lost workforce productivity, and substantial burdens on federal health programs like Medicare and Medicaid.
US VISION LOSS ECONOMIC BURDEN — ANNUAL COSTS (2017 DATA)
=============================================================
Total annual economic burden ████████████████████ $134.2 billion
Direct costs (medical/nursing) ████████████████░░░░ $98.7 billion
Indirect costs (productivity) ████░░░░░░░░░░░░░░░░ $35.5 billion
LARGEST INDIVIDUAL COST COMPONENTS:
Medical costs ████████████████████ $53.5 billion
Nursing home costs ███████████████░░░░░ $41.8 billion
Reduced labor force ██████░░░░░░░░░░░░░░░ $16.2 billion
participation
| Cost Category | Annual Amount (USD) | Source |
|---|---|---|
| Total US economic burden of vision loss/blindness (2017) | $134.2 billion | Rein DB et al., Ophthalmology, 2022 (CDC-funded) |
| Direct costs (medical, nursing home, supportive services) | $98.7 billion | Same study |
| Indirect costs (absenteeism, lost production, informal care) | $35.5 billion | Same study |
| Medical costs specifically | $53.5 billion | Same study |
| Nursing home costs specifically | $41.8 billion | Same study |
| Reduced labor force participation costs | $16.2 billion | Same study |
| Average annual cost per affected person | $16,838 | Same study |
| Medicare payments for 4 major eye conditions (2018) | $10.2 billion | Wittenborn JS et al., Ophthalmic Epidemiology, 2021 |
| Share of Medicare FFS beneficiaries with eye-disease claims | 41% | Same study |
| Projected total cost of vision problems by 2050 | $717 billion | Prevent Blindness, National Economic Impact study |
Source: Rein DB, Wittenborn JS, Zhang P, et al., “The Economic Burden of Vision Loss and Blindness in the United States,” Ophthalmology, 2022 (CDC Vision Health Initiative-funded); Wittenborn JS, Gu Q, Erdem E, et al., Ophthalmic Epidemiology, 2021 (CDC-funded Medicare analysis)
The CDC-funded national cost study, published in the peer-reviewed journal Ophthalmology, represents the most authoritative economic analysis of vision loss available, establishing that the condition imposes a $134.2 billion annual burden on the US economy. The data reveals that direct costs ($98.7 billion) dramatically outweigh indirect costs ($35.5 billion), with nursing home expenses alone reaching $41.8 billion annually — a figure that reflects how severely vision loss can compromise older adults’ ability to live independently, often accelerating the need for residential long-term care. This single cost category underscores why public health officials increasingly frame vision health as a critical determinant of healthy aging and independent living, not merely an isolated sensory impairment.
The burden on federal health programs is similarly substantial. A separate CDC-funded study analyzing Medicare fee-for-service claims data found that 41% of all Medicare beneficiaries had at least one claim related to cataracts, diabetic retinopathy, glaucoma, or age-related macular degeneration, with the program paying out $10.2 billion in 2018 alone for these four conditions combined. With age-related macular degeneration treatment averaging $1,290 per patient annually — the highest per-patient cost among the four major conditions studied — and overall vision-related healthcare costs projected by Prevent Blindness to reach $717 billion by 2050, the trajectory of vision care spending represents one of the more significant looming pressures on the US healthcare financing system as the population continues to age.
Vision Loss Risk Factors and Prevention in the US 2024
Beyond age and genetics, a range of modifiable behavioral and health-related risk factors significantly influence an individual’s likelihood of developing vision loss, offering meaningful opportunities for prevention through targeted public health intervention.
VISION LOSS RISK FACTOR PROFILE — US ADULTS 2024
====================================================
Chronic disease comorbidity (diabetes, HTN, heart dz) ████████████████░░░░ Elevated risk
Smoking ████████████████████ Major modifiable risk
Physical inactivity ████████████████░░░░ Documented risk factor
Diabetic patients skipping recommended eye exams ████████████████████ Up to 50%
Vitamin therapy reduction in AMD progression ████████████░░░░░░░░ 7.0% → 5.6%
Cataract surgery cost-effectiveness range ████████░░░░░░░░░░░░ $54–$3,654 per patient
| Risk Factor / Prevention Strategy | Statistic / Effect | Source |
|---|---|---|
| Chronic disease as risk multiplier (diabetes, hypertension, heart disease) | Documented elevated risk | CDC, Health Equity & Vision Loss, 2024/2026 |
| Smoking | Major behavioral risk factor | CDC, Health Equity & Vision Loss |
| Physical inactivity | Documented risk factor | CDC, Health Equity & Vision Loss |
| Diabetic retinopathy patients skipping recommended exams | Up to 50% | CDC, About Common Eye Disorders, 2025 |
| AMD progression to vision impairment without vitamin therapy | 7.0% of early AMD patients | CDC-funded cost-effectiveness model, Ophthalmology, 2007 |
| AMD progression to vision impairment with vitamin therapy | Reduced to 5.6% | Same study |
| Cataract surgery cost range (per patient) | $54–$3,654 | PMC systematic review, eClinicalMedicine, 2022 |
| Glaucoma treatment cost range (per patient) | $351–$1,354 | Same review |
| AMD treatment cost range (per patient) | $2,209–$7,524 | Same review |
Source: CDC, Advancing Health Equity: Social Determinants and Vision Loss, updated 2026; CDC, About Common Eye Disorders and Diseases, updated 2025; Rein DB et al., Cost-effectiveness of Vitamin Therapy for AMD, Ophthalmology, 2007 (CDC-funded); systematic review, eClinicalMedicine, 2022
The CDC’s health equity research consistently identifies a cluster of modifiable risk factors that significantly elevate an individual’s chances of developing serious vision loss, chief among them chronic conditions such as diabetes, high blood pressure, and heart disease, alongside behavioral factors including smoking and physical inactivity. These findings carry an important practical implication: a meaningful share of the nation’s vision loss burden is, in principle, preventable or delayable through improved chronic disease management and lifestyle modification, rather than being an inevitable consequence of aging alone. Yet the persistent finding that up to 50% of diabetic patients are not receiving timely, recommended eye examinations reveals a substantial and addressable gap between known prevention strategies and their real-world implementation across the healthcare system.
Targeted clinical interventions have also demonstrated measurable success in reducing vision loss progression. A CDC-funded cost-effectiveness model published in Ophthalmology found that antioxidant vitamin and zinc supplementation reduced the rate of progression to vision-impairing AMD from 7.0% to 5.6% among patients with early-stage disease, demonstrating that even modest, low-cost interventions can meaningfully alter long-term outcomes for a specific high-risk population. Looking at treatment economics more broadly, a comprehensive systematic review found substantial variation in per-patient treatment costs across the major causes of vision loss, with cataract surgery costs ranging from $54 to $3,654 and AMD treatment costs reaching as high as $7,524 per patient, reflecting the wide diversity of healthcare systems, insurance structures, and treatment intensities represented in the global cost literature. This data reinforces the public health case for early detection through routine comprehensive eye exams, since nearly every leading cause of vision loss in America responds far better to intervention when caught before substantial, irreversible damage has occurred.
Disclaimer: The data research report we present here is based on information found from various sources. We are not liable for any financial loss, errors, or damages of any kind that may result from the use of the information herein. We acknowledge that though we try to report accurately, we cannot verify the absolute facts of everything that has been represented.
